Caris Life Sciences (CAI) Change in Accured Expenses (2024 - 2026)

Caris Life Sciences' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at -$15.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 680.5% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at -$6.1 million (changed N/A YoY), while the FY2025 annual figure was $11.5 million, up 1329.51% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$15.0 million, down from $29.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $29.3 million in Q4 2025, with the low at -$21.3 million in Q2 2025.
• The 3-year median for Change in Accured Expenses is $889000.0 (2025), against an average of -$732000.0.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses jumped 105.4% in 2025, then plunged 680.5% in 2026.
• Caris Life Sciences' Change in Accured Expenses stood at $14.8 million in 2024, then jumped by 97.46% to $29.3 million in 2025, then tumbled by 151.17% to -$15.0 million in 2026.
• Business Quant data shows CAI's Change in Accured Expenses at -$15.0 million in Q1 2026, $29.3 million in Q4 2025, and $889000.0 in Q3 2025.